Latest & greatest articles for adalimumab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adalimumab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adalimumab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adalimumab

81. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy

Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy Infliximab, adalimumab and golimumab Infliximab, adalimumab and golimumab for treating moder for treating moderately to se ately to sev verely activ erely active e ulcer ulcerativ ative colitis after the failure of e colitis after the failure of con conv ventional ther entional therap apy y T echnology appraisal guidance Published: 25 February 2015 (...) and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Infliximab, adalimumab

2015 National Institute for Health and Clinical Excellence - Technology Appraisals

82. Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study (PubMed)

Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study A disease activity-guided dose optimisation strategy of adalimumab or etanercept (TNFi (tumour necrosis factor inhibitors)) has shown to be non-inferior in maintaining disease control in patients with rheumatoid arthritis (RA) compared with usual care. However, the cost-effectiveness of this strategy

2015 EvidenceUpdates

83. Adalimumab (humira) for treatment of pediatric Crohn's disease

Adalimumab (humira) for treatment of pediatric Crohn's disease Adalimumab (humira) for treatment of pediatric Crohn's disease Adalimumab (humira) for treatment of pediatric Crohn's disease HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Adalimumab (humira) for treatment of pediatric Crohn's disease. Lansdale: HAYES, Inc.. Healthcare (...) Technology Brief Publication. 2015 Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Adalimumab; Antibodies, Monoclonal; Child; Crohn Disease; Humans Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com

2015 Health Technology Assessment (HTA) Database.

84. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial (Full text)

Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial CONCERTO was a randomised, double-blind, parallel-armed study of methotrexate (MTX) in combination with adalimumab to assess whether an increasing trend of efficacy and decreased safety exists when increasing MTX dose in patients with early rheumatoid arthritis (RA).Early, biologic and MTX-naive RA patients (N=395) were evenly randomised to open-label adalimumab (40 mg every other (...) College of Rheumatology 50/70/90 responses with increasing doses of MTX in combination with adalimumab. No statistical differences in minimal clinically important differences in physical function were detected. Statistically significant trends for achieving low disease activity and remission were demonstrated with increasing MTX dose by validated clinical indices; differences comparing 10 and 20 mg MTX were minimal. Adalimumab serum concentrations increased with ascending dose up to 10 mg MTX. More

2014 EvidenceUpdates PubMed

85. Adalimumab, etanercept, infliximab and golimumab for the treatment of ankylosing spondylitis and reactive arthritis

Adalimumab, etanercept, infliximab and golimumab for the treatment of ankylosing spondylitis and reactive arthritis Adalimumab, etanercept, infliximab y golimumab para el tratamiento de las espondilitis anquilosante y artritis reactiva [Adalimumab, etanercept, infliximab and golimumab for the treatment of ankylosing spondylitis and reactive arthritis] Adalimumab, etanercept, infliximab y golimumab para el tratamiento de las espondilitis anquilosante y artritis reactiva [Adalimumab, etanercept (...) A, Ciapponi A, Mengarelli C. Adalimumab, etanercept, infliximab y golimumab para el tratamiento de las espondilitis anquilosante y artritis reactiva. [Adalimumab, etanercept, infliximab and golimumab for the treatment of ankylosing spondylitis and reactive arthritis] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rápida N° 294. 2013 Authors' objectives To assess the available evidence on the efficacy, safety and coverage related issues on the use

2014 Health Technology Assessment (HTA) Database.

86. Etanercept, adalimumab, infliximab and golimumab for the treatment of juvenile idiopathic arthritis

Etanercept, adalimumab, infliximab and golimumab for the treatment of juvenile idiopathic arthritis Etanercept, adalimumab, infliximab y golimumab para el tratamiento de artritis idiopática juvenil [Etanercept, adalimumab, infliximab and golimumab for the treatment of juvenile idiopathic arthritis] Etanercept, adalimumab, infliximab y golimumab para el tratamiento de artritis idiopática juvenil [Etanercept, adalimumab, infliximab and golimumab for the treatment of juvenile idiopathic arthritis (...) ] Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Alcaraz A, Lopez A, Rey-Ares L, Bardach A, Ciapponi A, Mengarelli C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Alcaraz A, Lopez A, Rey-Ares L, Bardach A, Ciapponi A, Mengarelli C. Etanercept, adalimumab, infliximab y

2014 Health Technology Assessment (HTA) Database.

87. Adalimumab

Adalimumab USE OF ADALIMUMAB IN PREGNANCY 0344 892 0909 USE OF ADALIMUMAB IN PREGNANCY (Date of issue: May 2015 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Adalimumab is a human monoclonal antibody administered in the treatment (...) of rheumatoid arthritis, enthesitis-related arthritis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, non-radiographic axial spondyloarthritis, psoriasis, Crohn’s disease, and ulcerative colitis. Its use in these conditions is reserved for patients where other systemic therapies are ineffective or unsuitable. There are very limited data specific to adalimumab use during pregnancy. Studies investigating the use of anti-TNFα therapies during pregnancy show no compelling evidence

2014 UK Teratology Information Service

88. Adalimumab (Humira) for severe chronic plaque psoriasis in children and adolescents ? second line

Adalimumab (Humira) for severe chronic plaque psoriasis in children and adolescents ? second line Adalimumab (Humira) for severe chronic plaque psoriasis in children and adolescents – second line Adalimumab (Humira) for severe chronic plaque psoriasis in children and adolescents – second line NIHR HSC Citation NIHR HSC. Adalimumab (Humira) for severe chronic plaque psoriasis in children and adolescents – second line. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review

2014 Health Technology Assessment (HTA) Database.

89. Adalimumab (Humira®)

Adalimumab (Humira®) Adalimumab (Humira®) Adalimumab (Humira®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Adalimumab (Humira®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat (...) Assessment Report Advice No. 2013. 2013 Authors' conclusions Adalimumab (Humira®) is recommended as an option for use within NHS Wales for the treatment of severe active Crohn's disease in paediatric patients (6 to 17 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy, a corticosteroid, and an immunomodulator, or who are intolerant to or have contraindications for such therapies. Final publication URL Indexing Status Subject indexing assigned

2013 Health Technology Assessment (HTA) Database.

90. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial (Full text)

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial To compare over 2 years the safety, efficacy and radiographic outcomes of subcutaneous abatacept versus adalimumab, in combination with methotrexate (MTX), in patients with rheumatoid arthritis (RA).AMPLE is a phase IIIb, 2-year, randomised, investigator-blinded study with a 1-year primary endpoint. Biologic-naive patients with active RA (...) and an inadequate response to MTX were randomised to 125 mg abatacept weekly or 40 mg adalimumab bi-weekly, both with a stable dose of MTX.Of 646 patients randomised, 79.2% abatacept and 74.7% adalimumab patients completed year 2. At year 2, efficacy outcomes, including radiographic, remained comparable between groups and with year 1 results. The American College Rheumatology 20, 50 and 70 responses at year 2 were 59.7%, 44.7% and 31.1% for abatacept and 60.1%, 46.6% and 29.3% for adalimumab. There were similar

2013 EvidenceUpdates PubMed

91. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. (PubMed)

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Biological agents offer good control of rheumatoid arthritis, but the long-term benefits of achieving low disease activity with a biological agent plus methotrexate or methotrexate alone are unclear. The OPTIMA trial assessed different treatment adjustment strategies in patients with early (...) rheumatoid arthritis attaining (or not) stable low disease activity with adalimumab plus methotrexate or methotrexate monotherapy.This trial was done at 161 sites worldwide. Patients with early (<1 year duration) rheumatoid arthritis naive to methotrexate were randomly allocated (by interactive voice response system, in a 1:1 ratio, block size four) to adalimumab (40 mg every other week) plus methotrexate (initiated at 7·5 mg/week, increased by 2·5 mg every 1-2 weeks to a maximum weekly dose of 20 mg

2013 Lancet

92. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial (PubMed)

Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial To evaluate the effect of adding a 10-week treatment of adalimumab to a standardised treatment with corticosteroids on the ability to taper more rapidly corticosteroid doses in patients with newly diagnosed giant cell arteritis (GCA).Patients included in this double-blind, multicentre controlled trial were randomly assigned to receive a 10-week subcutaneous treatment (...) of adalimumab 40 mg every other week or placebo in addition to a standard prednisone regimen (starting dose 0.7 mg/kg per day). The primary endpoint was the percentage of patients in remission on less than 0.1 mg/kg of prednisone at week 26. Analysis was performed by intention to treat (ITT).Among the 70 patients enrolled (adalimumab, n=34; placebo, n=36), 10 patients did not receive the scheduled treatment, seven in the adalimumab and three in the placebo group. By ITT, the number of patients achieving

2013 EvidenceUpdates

93. Adalimumab (Humira®)

Adalimumab (Humira®) Adalimumab (Humira®) Adalimumab (Humira®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Adalimumab (Humira®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat (...) Assessment Report Advice No. 2113. 2013 Authors' conclusions Adalimumab (Humira®) is recommended as an option for use within NHS Wales, in combination with methotrexate, for the treatment of active polyarticular juvenile idiopathic arthritis, in children aged 2 to 4 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Adalimumab can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate

2013 Health Technology Assessment (HTA) Database.

94. Adalimumab (Humira®)

Adalimumab (Humira®) Adalimumab (Humira®) Adalimumab (Humira®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Adalimumab (Humira®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat (...) Assessment Report Advice No.1513. 2013 Authors' conclusions Adalimumab (Humira®) is recommended for use within NHS Wales for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of ankylosing spondylitis but with objective signs of inflammation by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have had an inadequate response to, or are intolerant to non steroidal anti-inflammatory drugs (NSAIDs). Final publication URL Indexing Status

2013 Health Technology Assessment (HTA) Database.

95. Humira (Adalimumab, Abbott Laboratories) for treatment of pediatric crohn's disease

Humira (Adalimumab, Abbott Laboratories) for treatment of pediatric crohn's disease Humira (Adalimumab; Abbott Laboratories) for treatment of pediatric crohn's disease Humira (Adalimumab; Abbott Laboratories) for treatment of pediatric crohn's disease Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Humira (Adalimumab; Abbott Laboratories) for treatment

2013 Health Technology Assessment (HTA) Database.

96. Adalimumab (Humira) - in combination with methotrexate, for the treatment of active polyarticular juvenile idiopathic arthritis

Adalimumab (Humira) - in combination with methotrexate, for the treatment of active polyarticular juvenile idiopathic arthritis All Wales Medicines Strategy Group (AWMSG) - adalimumab (Humira) | | Appraisal information Search and reports adalimumab (Humira®) Reference No. 1977 Publication date: 15/08/2013 Appraisal information adalimumab (Humira®) 40 mg solution for injection Company: AbbVie Ltd BNF category: Musculoskeletal and joint diseases NMG meeting date: 19/06/2013 AWMSG meeting date: 17 (...) /07/2013 Submission Type: Limited Submission Status: Superseded Advice No: 2113 Ratification by Welsh Government: 14/08/2013 Current Progress Submission received NMG meeting AWMSG meeting Ratification by Welsh Government AWMSG advice AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA373) NICE GUIDANCE ISSUED DECEMBER 2015 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Adalimumab (Humira®) is recommended as an option

2013 All Wales Medicines Strategy Group

97. Adalimumab (Humira) - ankylosing spondylitis

Adalimumab (Humira) - ankylosing spondylitis All Wales Medicines Strategy Group (AWMSG) - adalimumab (Humira) | | Appraisal information Search and reports adalimumab (Humira®) Reference No. 1381 Publication date: 31/07/2013 Appraisal information adalimumab (Humira®) 40 mg solution for injection Company: AbbVie Ltd BNF category: Musculoskeletal and joint diseases NMG meeting date: 15/05/2013 AWMSG meeting date: 12/06/2013 Submission Type: Full Submission Status: Superseded Advice No: 1513 (...) Ratification by Welsh Government: 29/07/2013 Current Progress Submission received NMG meeting AWMSG meeting Ratification by Welsh Government AWMSG advice AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA383) NICE GUIDANCE ISSUED FEBRUARY 2016 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Adalimumab (Humira®) is recommended for use within NHS Wales for the treatment of adults with severe axial spondyloarthritis without

2013 All Wales Medicines Strategy Group

98. Adalimumab - Juvenile Idiopathic Arthritis

Adalimumab - Juvenile Idiopathic Arthritis Common Drug Review CDEC Meeting — June 19, 2013 Notice of CDEC Final Recommendation — July 18, 2013 Page 1 of 5 © 2013 CADTH CDEC FINAL RECOMMENDATION ADALIMUMAB (Humira — AbbVie Corporation) New Indication: Polyarticular Juvenile Idiopathic Arthritis Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that adalimumab be listed for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) if the following clinical criterion (...) and condition are met: Clinical Criterion: ? Inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs). Condition: ? Treatment should be initiated by a rheumatologist who is familiar with the use of DMARDs and/or biologic DMARDs in children. Reason for the Recommendation: One double-blind randomized controlled trial (RCT) (DE038; N = 133) demonstrated that adalimumab was superior to placebo for reducing the proportion of patients experiencing a disease flare, with or without

2013 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

100. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, (Full text)

Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, An investigator-initiated, double-blinded, placebo-controlled, treat-to-target protocol (Clinical Trials:NCT00660647) studied whether adalimumab added to methotrexate and intra-articular triamcinolone as first-line treatment in early (...) rheumatoid arthritis (ERA) increased the frequency of low disease activity (DAS28CRP<3.2) at 12 months.In 14 Danish hospital-based clinics, 180 disease-modifying anti-rheumatic drugs (DMARD)-naïve ERA patients (<6 months duration) received methotrexate 7.5 mg/week (increased to 20 mg/week within 2 months) plus adalimumab 40 mg every other week (adalimumab-group, n=89) or methotrexate+placebo-adalimumab (placebo-group, n=91). At all visits, triamcinolone was injected into swollen joints (max. four joints

2013 EvidenceUpdates PubMed